For the Inventor, By the Inventor

Enter assignee name

Seattle, WA, United States of America

Oncogen

USPTO Granted Patents = 48

CIPO Patents = 2

Forward Citations = 1,601

Loading Chart...

Loading Chart...

45 inventors (with patents filed for the assignee):

Karl E Hellstrom (17 out of 32 patents)

Ingegerd E Hellstrom (16 out of 32 patents)

George J Todaro (13 out of 24 patents)

4. Hans Marquardt (10 out of 20 patents)

5. Mohammed Shoyab (9 out of 20 patents)

6. Joseph P Brown (8 out of 19 patents)

7. Daniel R Twardzik (7 out of 28 patents)

8. Anthony F Purchio (7 out of 13 patents)

9. Peter S Linsley (6 out of 77 patents)

10. Diane Horn (5 out of 9 patents)

11. Gregory D Plowman (3 out of 44 patents)

12. Timothy M Rose (3 out of 11 patents)

13. H Perry Fell (3 out of 8 patents)

14. Shiu-Lok Hu (3 out of 3 patents)

15. Mario N Lioubin (3 out of 3 patents)

Core Competencies:

Tumor Immunotherapy

Monoclonal Antibodies

Chimeric Proteins

TGF-beta

Polypeptides

Anti-idiotypic Antibodies

Growth Factors

Immunoconjugates

Cancer Treatment

Biologically Active Lipids

Therapeutic Antibodies

Vaccine Development

48 patents: Sort by Forward Citations

1. 6194200 - Expression systems for preparation of polypeptides in prokaryotic cells (2001-02-27),

2. 5786456 - Bp 50-specific antibodies and fragments thereof (1998-07-28),

3. 5766588 - Tumor immunotherapy using anti-idiotypic antibodies (1998-06-16),

4. 5645835 - Therapeutic antibody based fusion proteins (1997-07-08),

5. 5614610 - Tumor immunotherapy using anti-idiotypic antibodies (1997-03-25),

6. 5597578 - TGF-.beta. protein compositions for inhibition of cell proliferation (1997-01-28),

7. 5545548 - Thermally stable cytosine deaminase from saccharomyces (1996-08-13),

8. 5482856 - Production of chimeric antibodies by homologous recombination (1996-01-09),

9. 5340925 - Normal human growth regulatory receptor for TGF-.beta. (1994-08-23),

10. 5314995 - Therapeutic interleukin-2-antibody based fusion proteins (1994-05-24),

11. 5262177 - Recombinant viruses encoding the human melanoma-associated antigen (1993-11-16),

12. 5248666 - Methods for inhibiting neoplastic cell proliferation using platelet (1993-09-28),

13. 5247069 - Ligands and methods for augmenting B-cell proliferation (1993-09-21),

14. 5244793 - TGF-.beta.1/.beta.2: a novel chimeric transforming growth factor-beta (1993-09-14),

15. 5242824 - Monoclonal antibody to human carcinomas (1993-09-07),

Company Overview

Oncogen, based in Seattle, WA, specializes in the development of innovative polypeptide therapeutics aimed at advancing tumor immunotherapy. The company focuses on creating chimeric and monoclonal antibodies, as well as therapeutic antibody fusion proteins, to target various cancers, including melanoma. Additionally, Oncogen is engaged in research related to HIV inhibition and the modulation of transforming growth factor-beta, positioning itself at the forefront of cutting-edge biomedical solutions in the oncology and immunotherapy sectors.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

48 Patents

#56 in Seattle, WA

#165 in Washington

#7,288 in US

#14,561 in the World

Seattle, WA, United States of America

Oncogen

Forward Citations = 1,601

45 inventors:

Karl E Hellstrom (17 out of 32 patents)

Ingegerd E Hellstrom (16 out of 32 patents)

George J Todaro (13 out of 24 patents)

4. Hans Marquardt (10 out of 20 patents)

5. Mohammed Shoyab (9 out of 20 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Oncogen. Retrieved from https://idiyas.com/company/oncogen

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…